
A study found that p‐Akt, a protein associated with PTEN deficiency and melanoma tumorigenesis, is expressed in 32.1% of acral, 68.4% of Low-CSD, and 55.6% of High-CSD melanomas. NUAK2, another protein, is expressed in 46.4%, 76.3%, and 50.0% of these melanomas, respectively. Both p‐Akt and NUAK2 expression were linked to worse relapse-free survival (RFS) in primary melanoma patients and acral melanoma patients. Importantly, p‐Akt significantly impacted RFS (Hazard ratio = 4.454; p < .0001), especially in acral melanoma patients (Hazard ratio = 4.036; p = .0005). This suggests that p‐Akt expression can predict relapse in patients with primary melanomas, particularly those with acral melanomas.
Like
Save
Share